IOVA · NASDAQ · STOCK
Iovance Biotherapeutics (IOVA) Stock Analysis
$14.61
52W $1.76 – $15.30
64/100
$6.53B
-20.0
0.76
Is IOVA Bullish or Bearish?
Bullish.
Innellis AI committee rates Iovance Biotherapeutics, Inc. (IOVA) Buy with a composite score of 64/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +10.93 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -9.07 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.5% yoy -- genuine top-line momentum. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 73 is in overbought territory — Technical
- Weekly RSI at 93 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 67.2% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
64/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 7%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -40.5% -- cheap may mean cheap for a reason
Growth Analyst
bullish
85
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 34.5% YoY -- genuine top-line momentum
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 73 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 67.2% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 34 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 65.7 to 64.1.
- New bearish signals: 3 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: score 69->61 (-8); +2 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
72.9
Overbought
MACD Histogram
0.054
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.84
Inside Bands
Price vs Moving Averages
EMA 9
$13.37
Above
EMA 21
$12.04
Above
EMA 50
$9.78
Above
EMA 200
$5.95
Above
Fundamental Analysis
Valuation
67
Growth
70
Profitability
18
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-20.0×
P/B Ratio
8.94×
PEG Ratio
-0.36
Dividend Yield
0.00%
52W High
$15.30
52W Low
$1.76
Quality & Growth
ROE
-5596.7%
ROA
-4281.6%
Gross Margin
4840.1%
Operating Margin
-9113.7%
Revenue Growth YoY
—
Debt / Equity
0.06
AI Fundamental Assessment
P/E ratio of -20.0 (inexpensive relative to a 15-40x range); Price-to-book of 8.9x; PEG ratio of -0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -56.0%; Return on assets of -42.8%; Net margin of -89.1%; Gross margin of 48.4%; Current ratio of 4.35 (healthy short-term liquidity); Debt-to-equity of 0.06; Free cash flow per share is negative (-0.66); Most recent quarter beat estimates by 14.3%; EPS growth accelerating (-5.6% -> +42.1% QoQ); Analyst estimates rising over recent quarters
Get the Full IOVA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →